A 72-year-old male heavy smoker (50 pack-years) was found to have a 2.9 cm x 2.6 cm space-occupying lesion near the lung hilum and mild fibrotic changes of unclear origin during a routine examination in December 2020.  Further investigation via EBUS-TBNA pathological examination and PET-CT confirmed a diagnosis of squamous cell lung carcinoma (SqCLC; T1N1MO, stage IIb). Genomic sequencing showed no driver mutation for targeted therapy (ALK(\u2212), BRAF(\u2212), BRCA1(\u2212), BRCA2(\u2212), EGFR(\u2212), ERBB2(HER2)(\u2212), FGFR2(\u2212), FGFR3(\u2212), KIT(\u2212), KRAS(\u2212), MET(\u2212), NRAS(\u2212), NTRK1(\u2212), NTRK2 (\u2013), NTRK3(\u2212), PDGFRA(\u2212), RET(\u2212), ROS1(\u2212), and IDH2(+)). PD-L1 testing was positive (TPS=25%, IPS<1%, tested using a Ventana SP263 assay), with a tumor mutation burden of 7.26 Muts/Mb (tested using a next-generation sequencing (NGS) panel and paired with peripheral blood sample sequencing). Genetic mutations related to immunotherapy were assessed: CD274(-), PDCD1LG2(-), MLH1(-), MSH2(-), MSH6(-), PMS2(-), POLD1(-), POLE(-), TP53(+), ATM(-), ATR(-), BRIP1(-), CHEK2(-), FANCA(-), RAD50(-), PALB2(-), CHEK1(-), MRE11(-), PBRM1(-), MDM2(-), MDM4(-), DNMT3A(-), JAK1(-), JAK2(+), PTEN(-), STK11(-), CCND1(-), FGF19(-), FGF3(-), FGF4(-).